By Fineline Cube 
NeuShen Therapeutics, a Sino‑US biotech focused on central nervous system (CNS) disorders, announced the completion of its Series A+ financing round, raising tens of millions of US dollars. The round was led by Lilly Asia Ventures, with Pivotal BioVenture Partners participating as co‑investor. Existing shareholders Shanghai Healthcare Capital, Lapam Capital, and TTM Capital continued their support.
Financing Structure & Strategic Terms
| Item | Detail |
|---|---|
| Company | NeuShen Therapeutics (Sino‑US) |
| Financing Round | Series A+ |
| Amount Raised | Tens of millions of US dollars |
| Lead Investor | Lilly Asia Ventures |
| Co‑Investor | Pivotal BioVenture Partners |
| Existing Shareholders | Shanghai Healthcare Capital, Lapam Capital, TTM Capital |
| Use of Proceeds | Advance preclinical research and clinical trials for CNS drug pipeline |
| Focus Areas | Psychiatric disorders and neurodegenerative diseases |
| Development Stage | Preclinical‑stage |
Market Impact & Strategic Implications
- CNS Market Opportunity: Global CNS therapeutics market valued at $150 billion : in 2025, projected to exceed $200 billion : by 2030, driven by aging populations and unmet need in psychiatric and neurodegenerative diseases
- Lilly Asia Ventures Thesis: Investment reflects continued appetite for early‑stage CNS platforms with novel mechanisms, leveraging Lilly’s expertise in neuroscience drug development
- Platform Validation: Proceeds will accelerate multiple pipelines toward clinical trials, with potential IND filings expected 2027 :
- Competitive Position: NeuShen’s focus on breakthrough therapies positions it to compete with established players like Biogen, Roche, and Novartis in high‑value CNS indications
- Geographic Advantage: Sino‑US structure enables dual market access and potential partnerships with both Chinese and Western pharma giants
- Next Steps: Lead programs advancing to IND‑enabling studies; management plans to disclose pipeline details at upcoming neuroscience conferences
Forward‑Looking Statements
This brief contains forward‑looking statements regarding pipeline advancement timelines, clinical trial initiation, and revenue potential for NeuShen’s CNS therapies. Actual results may differ due to preclinical risks, competitive dynamics, and regulatory pathways.-Fineline Info & Tech